2015
ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia
Shivarov V, Gueorguieva R, Ivanova M, Tiu RV. ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia. Leukemia & Lymphoma 2015, 56: 1881-1883. PMID: 25308295, DOI: 10.3109/10428194.2014.974596.Peer-Reviewed Original Research
2013
DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients
Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leukemia Research 2013, 37: 1445-1450. PMID: 23962568, DOI: 10.1016/j.leukres.2013.07.032.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAML patientsEuropean Leukemia NetDNMT3A mutationsIndependent adverse prognostic factorPoor prognosis biomarkerAdverse prognostic factorSubgroup of patientsPotential prognostic valueHigh-risk genotypesRecurrent molecular aberrationsDNMT3A mutational statusShorter OSShorter RFSYounger patientsPrognostic factorsRisk stratificationWorse prognosisPrognostic valueAML subtypesMyeloid leukemiaPrognosis biomarkerPatientsMolecular aberrationsRisk genotypes